Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fesoterodine - Pfizer

Drug Profile

Fesoterodine - Pfizer

Alternative Names: Fesosterodine; Fesoterodine fumarate; PF-00695838; PF-695838; SPM 007; SPM 907; Toviaz

Latest Information Update: 15 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schwarz Pharma
  • Developer Pfizer
  • Class Antispasmodics; Benzhydryl compounds; Esters; Propionic acids; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Stress incontinence

Most Recent Events

  • 08 May 2020 Pfizer completes a phase III trial in Overactive bladder (In children, In adolescents) in Japan (NCT02501928)
  • 13 Feb 2020 Pfizer completes a phase III trial in Overactive bladder (In children, In adolescents) in USA, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, India, Italy, Japan, Lithuania, Malaysia, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey and United Kingdom (PO) (NCT01557244)
  • 31 Jan 2020 Pfizer completes a phase II trial for Overactive bladder in Germany (PO, Tablet) (NCT02240459)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top